Oxford Cancer Analytics

What Oxford Cancer Analytics does

Oxford Cancer Analytics (OXcan) is a privately held medtech company founded in 2020 and headquartered in Oxford, United Kingdom, that develops AI-powered proteomics blood tests for the early detection and assessment of lung cancer and other respiratory diseases, starting with Chronic Obstructive Pulmonary Disease (COPD). The company's core platform, DEcancer, combines untargeted mass spectrometry-based proteomics — profiling thousands of protein features per patient from a single blood plasma sample — with proprietary machine learning algorithms that detect disease-linked biomarker signatures and integrate them with patient clinical context. OXcan reports that its ML framework doubled detection sensitivity from the 40% range to 80% while maintaining 99% specificity across eight cancer types, with the work published in iScience (Cell Press).

The company is pre-revenue and pre-commercial: pricing is not publicly disclosed, products are not yet commercially available, and the disclosed revenue model is the future sale of liquid biopsy diagnostic tests to healthcare systems, hospitals, and clinics. OXcan operates an enterprise field-sales motion through global partnerships with healthcare centres, universities, clinicians, and scientists, with stated collaborations at over 20 healthcare centres across three continents including NHS Oxford University Hospitals, UHN Princess Margaret Cancer Centre, and Oxford Radcliffe Biobank. The company is ISO 13485 certified for its biomarker discovery and validation platform, holds a patent on the DEcancer framework, and has raised US$16.7M in cumulative funding across a 2021 seed (£1.28M / $1.77M), a January 2023 seed ($3.7M led by Eka Ventures), and a January 2025 Series A ($11M led by We Venture Capital and Cross-Border Impact Ventures). Operations span Oxford (UK headquarters, with a new 2,400 sq ft lease at the Inventa building secured in November 2025), Toronto, Canada (MaRS South Tower), and Aurora, Colorado (USA).

Name

Oxford Cancer Analytics

Legal name

Oxford Cancer Analytics

Website

https://oxcan.org

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

Oxford Cancer Analytics (OXcan) develops AI-powered proteomics blood tests for early detection of lung cancer and COPD, using its proprietary DEcancer machine learning platform to analyse plasma proteomes for clinical use by healthcare systems and hospitals.

Ownership category

akta.pro rank

Product category

Cancer Diagnostics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)

akta.pro primary industry

Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)

akta.pro secondary industries

Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing (HLAAANAG), Proteomics & Biomarker Analytical Testing (HLAGADAG), Proteomics & Mass Spectrometry Services (HLAGANAB), AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)

Keywords

• Liquid biopsy diagnostics
• Proteomics biomarker discovery
• Early cancer detection
• AI diagnostic platform
• Lung disease screening

Headquarters

HQ city

Oxford

HQ country

United Kingdom

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Others

Revenue model

1. Liquid Biopsy Diagnostic Tests: OXcan is developing blood-based liquid biopsy tests for early cancer detection using advanced proteomics and AI. The company plans to commercialize these tests globally for lung cancer screening and management. Revenue will be generated through test sales to healthcare systems, hospitals, and clinics.
2. Diagnostic Testing Services: The company is focused on developing and deploying a simple blood test for early lung cancer detection. Once commercialized, the test will be offered to healthcare providers for routine screening of high-risk populations.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Core offering

Oxford Cancer Analytics develops minimally invasive blood-based diagnostic tests powered by its proprietary DEcancer AI platform, which combines untargeted mass spectrometry-based proteomics with machine learning to detect disease-linked protein signatures for early lung cancer and lung disease detection. The products are designed to integrate into existing clinical workflows and screening programs, supporting risk profiling and diagnostic evaluation for high-risk populations.

Product overview

Oxford Cancer Analytics offers a single unified product platform centered on its DEcancer platform, which combines advanced untargeted proteomics measurements from blood plasma with cutting-edge AI/machine learning to enable early lung cancer detection through liquid biopsy blood tests. The platform profiles thousands of protein features per patient, uses proprietary ML algorithms to detect disease-linked patterns, and integrates clinical context to support risk profiling and diagnostic evaluations. The company has achieved ISO 13485 certification status and is focused on respiratory diseases and lung cancer, with broader applicability across deadly cancers.

Differentiator

Problem solved

Functional benefit

Products and services

• DEcancer Platform AI-powered proteomics platform that performs deep profiling of blood plasma using mass spectrometry and proprietary machine learning to detect disease-linked protein signatures for lung disease and lung cancer detection. Designed for healthcare providers and clinical researchers.
• Lung Cancer Liquid Biopsy Blood Test Minimally invasive blood test for early lung cancer detection using advanced untargeted proteomics and AI, providing molecular signatures for patients at high risk of lung cancer with broader applicability to COPD. Intended for healthcare systems, hospitals, and clinics for routine screening.

Quantifiable outcome

• Detection rates doubled from 40% to 80% sensitivity while maintaining 99% specificity across eight cancer types
• +2 more outcomes

Named customers3 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature4 records

Partnerships

Seven partnerships are on record, tiered core and supporting.

• Prior LabscoreTechnology or Integration · 12 November 2025OXcan partners with Prior Labs to apply TabPFN (Tabular Prior-Data Fitted Networks) foundation models to high-clinical-need lung diseases. The collaboration aims to improve differentiation across complex disease stages and strengthen diagnostic capabilities for guiding treatment decisions through cutting-edge analytics integrated into clinical workflows.
• Francis Crick InstitutecoreStrategic or Co-development PartnerGlobal collaborator and supporter, providing research expertise and accelerator programme support through KQ Labs.
• Oxford UniversitycoreStrategic or Co-development PartnerAcademic research partner including collaborations with Oxford University Hospitals NHS Foundation Trust and the Oxford Radcliffe Biobank for clinical studies.
• Cancer Research UKcoreStrategic or Co-development PartnerMajor supporter and collaborator in cancer research initiatives and early cancer detection programmes.
• UHN (Princess Margaret Cancer Centre)coreStrategic or Co-development PartnerHealthcare centre collaborator based in Toronto for advancing liquid biopsy and clinical decision making in lung disease.
• NHS Oxford University HospitalscoreStrategic or Co-development PartnerNHS foundation trust collaborator for clinical studies and implementation of lung cancer detection technology.
• Sun Yat Sen UniversitysupportingStrategic or Co-development PartnerInternational academic collaborator in China for lung disease research and development.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Biodesix: Direct comparable as a proteomics-based lung cancer diagnostics company. OXcan's CTO Dr. Heinrich Roder founded Biodesix and scaled it to Nasdaq IPO with $50M annual revenue on a lung cancer liquid biopsy proteomics product - making this the closest operational and technological analog.
• Delfi Diagnostics: Liquid biopsy company developing blood-based cancer detection tests. Highly relevant given OXcan board member Jenn Buechel was previously President/COO at Delfi - indicating close operational familiarity and direct competitive overlap in early cancer detection.
• Oncimmune: UK-based lung cancer early detection company with blood-based tests (EarlyCDT Lung). Direct comparable given lung cancer focus, blood-based approach, and UK operations - representing the most geographically and indication-matched peer.
• Freenome: Multi-cancer early detection company using blood-based screening. Competes in similar multi-cancer liquid biopsy space and has raised substantial capital (>$1B) - representing a key strategic comparable for OXcan's multi-cancer expansion plans.

Broad incumbents

• GRAIL: Multi-cancer early detection blood test developer (Galleri). Competes directly with OXcan's multi-cancer aspirations from the iScience publication. Significantly more capitalized but the most direct multi-cancer blood test comparable.
• Natera: Public diagnostics company with multiple blood-based tests including Signatera for MRD monitoring. Comparable as a commercial-stage liquid biopsy company with established clinical and reimbursement infrastructure.
• Exact Sciences: Cancer diagnostics leader with Cologuard and expanding into multi-cancer detection (acquired Thrive Earlier Detection). Represents a potential strategic acquirer and benchmark for commercial-stage cancer diagnostic companies with blood-based tests.
• Guardant Health: Leading liquid biopsy company with FDA-approved tests across multiple cancer indications. While broader in scope and better capitalized, both companies use blood-based approaches for cancer detection, making it a key incumbent comparable for technology and commercialization benchmarking.

Others

• Olink: Proteomics platform provider whose technology is widely used in biomarker discovery. Adjacent/ecosystem participant as a potential technology supplier and benchmark for proteomics-enabled diagnostic development, though not a direct competitor.

Emerging players

• Proteomics International: Smaller proteomics-based diagnostics company developing blood tests for various diseases. Comparable as an emerging proteomics diagnostics player, though focused on different indications (diabetes, Alzheimer's) rather than cancer.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/oxford-cancer-analytics

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles18 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Oxford Cancer Analytics